5
Participants
Start Date
March 31, 2013
Primary Completion Date
July 31, 2016
Study Completion Date
October 31, 2016
NKAE cells infusion
Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
Lenalidomide
Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
Bortezomib
Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
Hospital Universitario 12 de Octubre, Madrid
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
OTHER
Joaquín Martínez López, MD, PhD
OTHER